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Background
Several treatment options have been described for chronic
rhinosinusitis (CRS), yet many patients remain poorly
responsive to medical and surgical therapy. Recently, anti-
IgE monoclonal antibody has emerged as a potential ther-
apy for CRS. However, to date evidence for its efficacy in
this patient population is sparse. The purpose of this study
is to evaluate the clinical effect of anti-IgE monoclonal
antibody therapy for patients with recalcitrant CRS and
asthma treated in a multi-disciplinary clinic.
Methods
A review of the charts for the 194 patients on anti-IgE
monoclonal antibody therapy was performed. 20 patients
diagnosed with CRS with poorly controlled disease having
failed surgical and/or medical therapy were identified.
Data extraction targeted demographic details, asthma,
environmental allergy and CRS specific disease related
data. For data analysis, for nonparametric data the Mann-
Whitney test was used and for binary data Fisher’s exact
test was used.
Results
Mean age of the cohort was 49 years (range 33-67); ele-
ven patients were male. Mean IgE level was 331.14 IU/ml
(57.54-1338.96 IU/ml). Mean treatment duration was
17 (3-71) months. The most common skin prick test
positive environmental allergens were dust mite (100%)
and cat (65%). 75% of patients had CRS with polyps. Six
patients (30%) had AERD. The mean polyp score
decreased from 1.8 to 1.0 (p=0.106). Patient olfaction
improved in 11 patients (55%) with therapy. Two patients
on chronic prednisone treatment were able to discon-
tinue this treatment. None of the patients progressed to
require surgical treatment.
Conclusions
Anti-IgE monoclonal antibody therapy allowed for clini-
cal CRS disease control in this cohort of patients with
severe and recalcitrant CRS. A well-designed clinical
trial is needed to further assess the efficacy and safety of
this treatment in the CRS population.
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